Cited by 723HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Open access

Venter, Willem D.F., Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1902824

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries. METHODS: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data. RESULTS: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens. CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1902824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki, B., Kuosma, E., Ferrie, J. E., Luukkonen, R. A., Nyberg, S. T., Alfredsson, L. S., Batty, G. D., Brunner, E. J., Fransson, E. I., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 695
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J. M., & Shapiro, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 379
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Norwood, J., Turner, M. M., Bofill, C., Rebeiro, P. F., Shepherd, B. E., Bebawy, S. S., Hulgan, T., Raffanti, S. P., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 285
Brief Report
Walmsley, S. L., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, É., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 225
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
Bakal, D. R., Coelho, L. E., Luz, P. M., Clark, J. L., Boni, R. B. D., Cardoso, S. W., Veloso, V. G., Lake, J. E., & Grinsztejn, B. G. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky145 · Cited by 188
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A. E., Thompson, M., Brinson, C. C., Hagins, D. P., Ramgopal, M. N., Antinori, A., Wei, X., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30077-3 · Cited by 168

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 2

Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines: testing new directions in treatment and measuring impact. Presented at the Eighth International AIDS Society Conference Vancouver BC Canada July 19–22 2015.
Beyrer C, Pozniak A. HIV drug resistance. N Engl J Med 2018;378:875-875.29490186

Sorted by citations

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D. J., Clement, M. E., Hanscom, B. S., Cottle, L. M., Coelho, L. E., Cabello, R. L., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 934
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Sax, P. E., Erlandson, K. M., Lake, J. E., McComsey, G. A., Orkin, C. M., Eßer, S., Brown, T. T., Rockstroh, J. K., Wei, X., Carter, C. C., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz999 · Cited by 775
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Delany‐Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J. M., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 609
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Saag, M. S., Gandhi, R. T., Hoy, J., Landovitz, R. J., Thompson, M., Sax, P. E., Smith, D. M., Benson, C. A., Buchbinder, S., del Rı́o, C., et al. (2020) · JAMA · doi:10.1001/jama.2020.17025 · Cited by 497
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Venter, F., Sokhela, S. M., Simmons, B., Moorhouse, M. A., Fairlie, L., Mashabane, N., Serenata, C. M., Akpomiemie, G., Masenya, M. S., Qavi, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30241-1 · Cited by 274
Self-citation
Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
Bourgi, K., Jenkins, C. A., Rebeiro, P. F., Shepherd, B. E., Palella, F., Moore, R. D., Althoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25484 · Cited by 246
Update and latest advances in antiretroviral therapy
Menéndez‐Arias, L., & Delgado, R. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.004 · Cited by 229
HIV and antiretroviral therapy-related fat alterations
Koethe, J. R., Lagathu, C., Lake, J. E., Domingo, P., Calmy, A., Falutz, J., Brown, T. T., & Capeau, J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0181-1 · Cited by 234
Obesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
Weight gain and integrase inhibitors
Eckard, A. R., & McComsey, G. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000616 · Cited by 212
Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy
Lake, J. E., Wu, K., Bares, S. H., Debroy, P., Godfrey, C. C., Koethe, J. R., McComsey, G. A., Palella, F. J., Tassiopoulos, K., & Erlandson, K. M. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa177 · Cited by 205
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
Paton, N. I., Musaazi, J., Kityo, C. M., Walimbwa, S., Hoppé, A., Balyegisawa, A. P., Kaimal, A., Mirembe, G., Tukamushabe, P., Ategeka, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101609 · Cited by 175
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Lockman, S., Brummel, S. S., Ziemba, L., Stranix‐Chibanda, L., McCarthy, K., Coletti, A., Jean‐Philippe, P., Johnston, B., Krotje, C., Fairlie, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00314-7 · Cited by 167
Self-citation
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
Wassner, C., Bradley, N. E., & Lee, Y. (2020) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325958220919231 · Cited by 165
The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
Gorwood, J., Bourgeois, C., Pourcher, V., Pourcher, G., Charlotte, F., Mantecon, M., Rose, C., Morichon, R., Atlan, M., Grand, R. L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa259 · Cited by 158
Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa
Kiguba, R., Olsson, S., & Waitt, C. J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15193 · Cited by 158
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
Scarsi, K. K., Havens, J. P., Podany, A. T., Avedissian, S. N., & Fletcher, C. V. (2020) · Drugs · doi:10.1007/s40265-020-01379-9 · Cited by 151
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease
Obare, L. M., Temu, T. M., Mallal, S. A., & Wanjalla, C. N. (2024) · Circulation Research · doi:10.1161/circresaha.124.323891 · Cited by 150
Why and where an HIV cure is needed and how it might be achieved
Ndung’u, T., McCune, J. M., & Deeks, S. G. (2019) · Nature · doi:10.1038/s41586-019-1841-8 · Cited by 153
Prevention, treatment and cure of HIV infection
Landovitz, R. J., Scott, H. M., & Deeks, S. G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00914-1 · Cited by 153
Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future
Godman, B., Basu, D., Pillay, Y. G., Mwita, J. C., Rwegerera, G. M., Paramadhas, B. D. A., Tiroyakgosi, C., Okwen, P., Niba, L. L., Nonvignon, J., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00108 · Cited by 145
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
Orkin, C. M., Bernal, E., Tan, D. H. S., Katner, H. P., Stellbrink, H., Belonosova, E., DeMoor, R., Griffith, S. K., Thiagarajah, S., Solingen-Ristea, R. M. V., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00184-3 · Cited by 140
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Zhao, A., Crutchley, R. D., Guduru, R. C., Ton, K., Lam, T., & Min, A. (2022) · Retrovirology · doi:10.1186/s12977-022-00608-1 · Cited by 136
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
Kanters, S., Vitória, M., Zoratti, M. J., Doherty, M. C., Penazzato, M., Rangaraj, A., Ford, N. P., Thorlund, K., Anis, A. H., Karim, M. E., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100573 · Cited by 135
Weight gain before and after switch from TDF to TAF in a U.S. cohort study
Mallon, P. W. G., Brunet, L., Hsu, R. K., Fusco, J. S., Mounzer, K., Prajapati, G., Beyer, A. P., Wohlfeiler, M. B., & Fusco, G. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25702 · Cited by 135
Approved HIV reverse transcriptase inhibitors in the past decade
Li, G., Wang, Y., & Clercq, E. D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.009 · Cited by 137
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Turkova, A., White, E., Mujuru, H. A., Kekitiinwa, A. R., Kityo, C. M., Violari, A., Lugemwa, A., Cressey, T. R., Musoke, P., Variava, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108793 · Cited by 135
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
Surial, B., Mugglin, C., Calmy, A., Cavassini, M. L., Günthard, H. F., Stöckle, M., Bernasconi, E., Schmid, P., TARR, P. E., Furrer, H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-4853 · Cited by 132
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
Erlandson, K. M., Carter, C. C., Melbourne, K. M., Brown, T. T., Cohen, C. J., Das, M., Eßer, S., Huang, H., Koethe, J. R., Martin, H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab444 · Cited by 121
Evidence Synthesis Evaluating Body Weight Gain Among People Treating HIV with Antiretroviral Therapy - a Systematic Literature Review and Network Meta-Analysis
Kanters, S., Renaud, F., Rangaraj, A., Zhang, K., Limbrick‐Oldfield, E. H., Hughes, M., Ford, N. P., & Vitória, M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101412 · Cited by 114
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
Kityo, C. M., Mambule, I., Musaazi, J., Sokhela, S. M., Mugerwa, H., Ategeka, G., Cresswell, F. V., Siika, A. M., Kosgei, J., Shah, R., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00289-5 · Cited by 114
Self-citation
Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada
Rebeiro, P. F., Jenkins, C. A., Bian, A., Lake, J. E., Bourgi, K., Moore, R. D., Horberg, M. A., Mathews, W. C., Silverberg, M. J., Thorne, J. E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1403 · Cited by 110
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
Smith, S. J., Zhao, X. Z., Passos, D. O., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13020205 · Cited by 110
Long-acting injectable cabotegravir for the prevention of HIV infection
Clement, M. E., Kofron, R., & Landovitz, R. J. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000597 · Cited by 110
Immunometabolism and HIV-1 pathogenesis: food for thought
Sáez‐Cirión, A., & Sereti, I. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0381-7 · Cited by 111
Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa
Brennan, A. T., Nattey, C., Kileel, E. M., Rosen, S. B., Maskew, M., Stokes, A. C., Fox, M. P., & Venter, F. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101836 · Cited by 102
The case for an HIV cure and how to get there
Dybul, M. R., Attoye, T., Baptiste, S. L., Cherutich, P., Dabis, F., Deeks, S. G., Dieffenbach, C. W., Doehle, B., Goodenow, M. M., Jiang, A., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30232-0 · Cited by 101
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Sax, P. E., Arribas, J. R., Orkin, C. M., Lazzarin, A., Pozniak, A., DeJesus, E., Maggiolo, F., Stellbrink, H., Yazdanpanah, Y., Acosta, R. K., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101991 · Cited by 98
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022
Waters, L. J., Winston, A., Reeves, I., Boffito, M., Churchill, D. R., Cromarty, B., Dunn, D. T., Fink, D., Fidler, S. J., Foster, C., et al. (2022) · HIV Medicine · doi:10.1111/hiv.13446 · Cited by 91
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Griesel, R., Maartens, G., Chirehwa, M., Sokhela, S. M., Akpomiemie, G., Moorhouse, M. A., Venter, F., & Sinxadi, P. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1073 · Cited by 90
Self-citation
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Siedner, M. J., Moorhouse, M. A., Simmons, B., de Oliveira, T., Lessells, R. J., Giandhari, J., Kemp, S. A., Chimukangara, B., Akpomiemie, G., Serenata, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19801-x · Cited by 84
Self-citation
Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop
Gabuzda, D. H., Jamieson, B. D., Collman, R. G., Lederman, M. M., Burdo, T. H., Deeks, S. G., Dittmer, D. P., Fox, H. S., Funderburg, N., Pahwa, S. G., et al. (2020) · Pathogens and Immunity · doi:10.20411/pai.v5i1.365 · Cited by 86
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era
Ruderman, S. A., Crane, H. M., Nance, R. M., Whitney, B. M., Harding, B. N., Mayer, K. H., Moore, R. D., Eron, J. J., Geng, E. H., Mathews, W. C., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002556 · Cited by 81
Residual immune dysfunction under antiretroviral therapy
Cai, C. W., & Sereti, I. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101471 · Cited by 80
Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus
O’Halloran, J. A., Sahrmann, J. M., Parra-Rodriguez, L., Vo, D. T., Butler, A. M., Olsen, M. A. A., & Powderly, W. G. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac355 · Cited by 79
Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study
Gupta‐Wright, A., Fielding, K., van Oosterhout, J. J., Alufandika, M., Grint, D. J., Chimbayo, E. T., Heaney, J., Byott, M., Nastouli, E., Mwandumba, H. C., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30172-7 · Cited by 78
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update
Nel, J. S., Dlamini, S. K., Meintjes, G., Burton, R., Black, J. M., Davies, N., Hefer, E., Maartens, G., Mangena, P., Mathe, M., et al. (2020) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v21i1.1115 · Cited by 78
Self-citation
Antiretrovirals and Weight Change: Weighing the Evidence
Wohl, D. A., Koethe, J. R., Sax, P. E., McComsey, G. A., Kuritzkes, D. R., Moyle, G. J., Kaplan, L. M., Wyk, J. A. V., Campo, R. E., & Cohen, C. J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae191 · Cited by 79
Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
Schafer, J. J., Sassa, K. N., O’Connor, J. R., Shimada, A., Keith, S. W., & DeSimone, J. A. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz414 · Cited by 77
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
Zhang, J., Lin, S.-Z., Jiang, D., Li, M., Chen, Y.-W., Li, J., & Fan, J.-G. (2020) · Liver international (Print) · doi:10.1111/liv.14369 · Cited by 73
Factors Associated With Weight Gain in People Treated With Dolutegravir
Taramasso, L., Bonfanti, P., Ricci, E. D., Orofino, G., Squillace, N., Menzaghi, B., Socio, G. V. D., Madeddu, G., Pellicanò, G. F., Pagnucco, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa195 · Cited by 76
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes
McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021) · AIDS · doi:10.1097/qad.0000000000002930 · Cited by 72
Self-citation
Physical activity and exercise to improve cardiovascular health for adults living with HIV
Ozemek, C., Erlandson, K. M., & Jankowski, C. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.01.005 · Cited by 71
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
The RESPOND Study Group∗ (2021) · AIDS · doi:10.1097/qad.0000000000002811 · Cited by 73
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Phillips, A. N., Bansi‐Matharu, L., Venter, F., Havlir, D. V., Pozniak, A., Kuritzkes, D. R., Wensing, A. M. J., Lundgren, J. D., Pillay, D., Mellors, J. W., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(19)30400-x · Cited by 71
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Lake, J. E., Overton, T., Naggie, S., Sulkowski, M., Loomba, R. S., Kleiner, D. E., Price, J. C., Chew, K. W., Chung, R. T., & Corey, K. E. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.018 · Cited by 70
Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study
Nanditha, N. G. A., Paiero, A., Tafessu, H. M., St‐Jean, M., McLinden, T., Justice, A. C., Kopec, J. A., Montaner, J. S. G., Hogg, R. S., & Lima, V. D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041734 · Cited by 69
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
Dorward, J., Sookrajh, Y., Khubone, T., van der Molen, J. S., Govender, R., Phakathi, S., Lewis, L., Bottomley, C., Maraj, M., Lessells, R. J., et al. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00047-4 · Cited by 69
Management of HIV-infected patients in the intensive care unit
Barbier, F., Mer, M., Szychowiak, P., Miller, R. F., Mariotte, É., Galicier, L., Bouadma, L., Tattevin, P., & Azoulay, É. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05945-3 · Cited by 67
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
Bansi‐Matharu, L., Phillips, A. N., Oprea, C., Grabmeier‐Pfistershammer, K., Günthard, H. F., Wit, S. D., Guaraldi, G., Vehreschild, J. J., Wit, F. W. N. M., Law, M. G., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00163-6 · Cited by 65
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV
Eke, A. C., Mirochnick, M. H., & Lockman, S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2212877 · Cited by 65
Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women
Summers, N. A., Lahiri, C. D., Angert, C. D., Aldredge, A., Mehta, C. C., Ofotokun, I., Kerchberger, A. M., Gustafson, D., Weiser, S. D., Kassaye, S., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002447 · Cited by 67
Ethical issues in therapeutic use and research in pregnant and breastfeeding women
Weld, E. D., Bailey, T. C., & Waitt, C. J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14914 · Cited by 65
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
Byonanebye, D. M., Polizzotto, M. N., Neesgaard, B., Sarcletti, M., Matulionytė, R., Braun, D. L., Castagna, A., Wit, S. D., Wit, F. W. N. M., Fontas, É., et al. (2022) · HIV Medicine · doi:10.1111/hiv.13273 · Cited by 64
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era
McCluskey, S. M., Pepperrell, T., Hill, A., Venter, W. D. F., Gupta, R. K., & Siedner, M. J. (2021) · AIDS · doi:10.1097/qad.0000000000003082 · Cited by 63
Self-citation
Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications
Chandiwana, N. C., Siedner, M. J., Marconi, V. C., Hill, A. M., Ali, M. K., Batterham, R. L., & Venter, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad411 · Cited by 62
Self-citation
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Kuo, P.-H., Sun, H.-Y., Chuang, Y.-C., Wu, P.-Y., Liu, W.-C., & Hung, C.-C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.12.029 · Cited by 61
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review
Chu, C., Tao, K., Kouamou, V., Avalos, A., Scott, J. A., Grant, P., Rhee, S., McCluskey, S. M., Jordan, M. R., Morgan, R. L., et al. (2024) · Viruses · doi:10.3390/v16030399 · Cited by 59
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG
Bosch, B., Akpomiemie, G., Chandiwana, N. C., Sokhela, S. M., Hill, A. M., McCann, K., Qavi, A., Mirchandani, M., & Venter, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac949 · Cited by 58
Self-citation
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts
Byonanebye, D. M., Polizzotto, M. N., Maltêz, F., Rauch, A., Grabmeier‐Pfistershammer, K., Wit, F. W. N. M., Wit, S. D., Castagna, A., Monforte, A. D., Mussini, C., et al. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(23)00328-4 · Cited by 58
No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV
Burns, J. E., Stirrup, O., Dunn, D. T., Runcie-Unger, I., Milinkovic, A., Candfield, S., Lukha, H., Severn, A., Waters, L. J., Edwards, S., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002379 · Cited by 58
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV
Lake, J. E., & Trevillyan, J. M. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000680 · Cited by 57
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
Leonard, M. A., Cindi, Z., Bradford, Y., Bourgi, K., Koethe, J. R., Turner, M. M., Norwood, J., Woodward, B., Erdem, H., Basham, R., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1219 · Cited by 57
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen
Taramasso, L., Berruti, M., Briano, F., & Biagio, A. D. (2020) · AIDS · doi:10.1097/qad.0000000000002496 · Cited by 56
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A. P. H., Chen, T., Reynolds, H. E., Read, L., Read, J., Stemmet, L.-A., Mrubata, M., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00173-4 · Cited by 56
Self-citation
Cardiovascular Implications of Immune Disorders in Women
Moran, C. A., Collins, L. F., Beydoun, N., Mehta, P. K., Fatade, Y., Isiadinso, I., Lewis, T. T., Weber, B., Goldstein, J. M., Ofotokun, I., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319877 · Cited by 57
Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes
Ayissi, K. N., Gorwood, J., Pelletier, L., Bourgeois, C., Beaupère, C., Auclair, M., Foresti, R., Motterlini, R., Atlan, M., Barrail‐Tran, A., et al. (2022) · Cells · doi:10.3390/cells11111841 · Cited by 51
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials
Pilkington, V., Hughes, S. L., Pepperrell, T., McCann, K., Gotham, D., Pozniak, A., & Hill, A. M. (2020) · AIDS · doi:10.1097/qad.0000000000002699 · Cited by 51
Self-citation
Diabetes in People with HIV
Sarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 53
Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment
Bourgeois, C., Gorwood, J., Olivo, A., Pelletier, L., Capeau, J., Lambotte, O., Béréziat, V., & Lagathu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670566 · Cited by 51
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents
Thivalapill, N., Simelane, T. T., Mthethwa, N., Dlamini, S., Lukhele, B. W., Okello, V., Kirchner, H. L., Mandalakas, A. M., & Kay, A. W. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1652 · Cited by 49
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens
Sokhela, S. M., Venter, F., Bosch, B., Woods, J., McCann, K., Akpomiemie, G., Chandiwana, N. C., Mashabane, N., Tembo, A., Simmons, B., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae007 · Cited by 48
Self-citation
Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients
Weichseldorfer, M. R., Reitz, M. S., & Latinovic, O. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111798 · Cited by 48
Weight gain during pregnancy among women initiating dolutegravir in Botswana
Caniglia, E. C., Shapiro, R., Diseko, M., Wylie, B. J., Zera, C., Davey, S. R., Isaacson, A., Mayondi, G. K., Mabuta, J., Luckett, R. L., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100615 · Cited by 47
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
Pyngottu, A., Scherrer, A., Kouyos, R. D., Huber, M., Hirsch, H. H., Perreau, M., Yerly, S., Calmy, A., Cavassini, M. L., Stöckle, M., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1614 · Cited by 46
Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
Mallon, P. W. G., Brunet, L., Fusco, J. S., Prajapati, G., Beyer, A. P., Fusco, G., & Wohlfeiler, M. B. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab621 · Cited by 46
Changes in weight and BMI with first-line doravirine-based therapy
Orkin, C. M., Elion, R., Thompson, M., Rockstroh, J. K., Bognar, F. A., Xu, Z. J., Hwang, C. K., Sklar, P. A., & Martin, E. A. (2020) · AIDS · doi:10.1097/qad.0000000000002725 · Cited by 45
A review of dolutegravir-associated weight gain and secondary metabolic comorbidities
Jemal, M. (2024) · SAGE Open Medicine · doi:10.1177/20503121241260613 · Cited by 45
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
Krakower, D., Daskalakis, D., Feinberg, J., & Marcus, J. L. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3337 · Cited by 44
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study
Esber, A. L., Dear, N. F., Neha, S., Hannah, K., Maswai, J. K., John, O., Sing’oei, V., Emmanuel, B., Michael, I., CROWELL, T. A., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003065 · Cited by 43
An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status
Shin, Y. H., Park, C. M., & Yoon, C. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2020.0100 · Cited by 43
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
Griesel, R., Zhao, Y., Simmons, B., Omar, Z., Wiesner, L., Keene, C., Hill, A. M., Meintjes, G., & Maartens, G. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00081-4 · Cited by 42
Self-citation
Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism
Savinelli, S., Newman, E., & Mallon, P. W. G. (2024) · Current HIV/AIDS Reports · doi:10.1007/s11904-024-00708-x · Cited by 41
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
Liu, Z., Jin, Q., Zhang, Y., Gong, G., Wu, G., Yao, L., Wen, X., Gao, Z., Huang, Y., Yang, D., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16611 · Cited by 41
Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
Domingo, P., Quesada‐López, T., Villarroya, J., Cairó, M., Gutiérrez, M. D. M., Mateo, G. M., Mur, I., Corbacho, N., Domingo, J. C., Villarroya, F., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120948 · Cited by 40
Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight
McMahon, C., Trevaskis, J. L., Carter, C. C., Holsapple, K., White, K., Das, M., Collins, S. E., Martin, H., & Burns‐Naas, L. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229617 · Cited by 41
Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV
O’Halloran, J. A., Sahrmann, J. M., Butler, A. M., Olsen, M. A. A., & Powderly, W. G. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002357 · Cited by 39
Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens
Milić, J., Renzetti, S., Ferrari, D., Barbieri, S., Menozzi, M., Carli, F., Dolci, G., Ciusa, G., Mussini, C., Calza, S., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003289 · Cited by 40
SIV Infection and the HIV Proteins Tat and Nef Induce Senescence in Adipose Tissue and Human Adipose Stem Cells, Resulting in Adipocyte Dysfunction
Gorwood, J., Ejlalmanesh, T., Bourgeois, C., Mantecon, M., Rose, C., Atlan, M., Desjardins, D., Grand, R. L., Fève, B., Lambotte, O., et al. (2020) · Cells · doi:10.3390/cells9040854 · Cited by 40
Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
Brown, J. A., Nsakala, B. L., Mokhele, K., Rakuoane, I., Muhairwe, J. A., Urda, L., Amstutz, A., Tschumi, N., Klimkait, T., & Labhardt, N. D. (2021) · HIV Medicine · doi:10.1111/hiv.13189 · Cited by 38

Authors: Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A.
Affiliations: From Ezintsha (W.D.F.V., M. Moorhouse, S.S., N.M., C.S., G.A., N.C., N.A., A.V.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences (W.D.F.V., M. Moorhouse, S.S., L.F., N.M., M. Masenya, C.S., G.A., N.C., M.C., N.A., A.V.), and the South African Medical Research Council Developmental Pathways for Health Research Unit, Department of Pediatrics, School of Clinical Medicine, Faculty of Health Sciences (S.N.), University of the Witwatersrand, Johannesburg; the Faculty of Medicine,...
South African Medical Research Council (ZA)
ORCID: Venter, Willem D.F.
Moorhouse, Michelle
Sokhela, Simiso
Fairlie, Lee
Mashabane, Nkuli
Masenya, Masebole
Serenata, Celicia
Akpomiemie, Godspower
Qavi, Ambar
Chandiwana, Nomathemba
Norris, Shane
Chersich, Matthew
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Vos, Alinda
McCann, Kaitlyn
Simmons, Bryony
Hill, Andrew
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-08-29
Volume: 381
Issue: 9
Pages: 803-815
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1902824
OpenAlex: W2962964639
Cited by: 723
References: 31
Citations by year: 2026: 65 · 2025: 84 · 2024: 117 · 2023: 110 · 2022: 90 · 2021: 112 · 2020: 120 · 2019: 25
FWCI: 66.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: UNITAID (2016-07-Wits RHI)
U.S. Agency for International Development (AID-OAA-A-15-00069)
South African Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: dolutegravir, tenofovir alafenamide, tenofovir disoproxil fumarate, HIV-1 infection, antiretroviral therapy, triple therapy, emtricitabine, efavirenz, non-inferiority, viral suppression, treatment discontinuation, low- and middle-income countries, South Africa
MeSH terms: Dolutegravir, Adenine, Adolescent, Adult, Drug Therapy, Combination, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Phosphorous Acids, Piperazines, Pregnancy, Pregnancy Complications, Infectious, Prodrugs, Pyridones, RNA, Viral, Uracil, HIV-1, Bone Density, HIV Infections, CD4 Lymphocyte Count, HIV Integrase Inhibitors, Viral Load, Anti-Retroviral Agents, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks